Progression after molecular targeted agents: Hepatic arterial changes and transarterial chemoembolization in hepatocellular carcinoma
N Matsuda, N Imai, T Kuzuya, K Yamamoto, T Ito… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: The purpose of this study was to determine changes in the hepatic arteries
after treatment with a molecular targeted agent (MTA), and evaluate the safety and efficacy …
after treatment with a molecular targeted agent (MTA), and evaluate the safety and efficacy …
Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization
O Matsui - Clinical drug investigation, 2012 - Springer
Transarterial chemoembolization (TACE) is the gold standard of treatment for intermediate-
stage hepatocellular carcinoma (HCC), and involves the administration of cytotoxic drugs …
stage hepatocellular carcinoma (HCC), and involves the administration of cytotoxic drugs …
[HTML][HTML] Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma
AA Haydar, D Mukherji, W Faraj… - Gastrointestinal …, 2014 - ncbi.nlm.nih.gov
BACKGROUND: The combination of systemic antiangiogenic therapy and transarterial
chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma …
chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma …
Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional …
S Lee, KM Kim, SJ Lee, KH Lee, DY Lee… - Acta …, 2017 - journals.sagepub.com
Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC)
frequently causes feeding artery stenosis or occlusion that may interfere with repeated …
frequently causes feeding artery stenosis or occlusion that may interfere with repeated …
OUTCOME OF TRANSARTERIAL CHEMOEMBOLIZATION IN KOREAN PATIENTS WITH HEPATOCELLULAR CARCINOMA: REFERENCE FOR A PROSPECTIVE …
HY Kim, JW Park, HK Park, SM Woo, JI Choi, HB Kim… - Hepatology, 2010 - journals.lww.com
BACKGROUND: The need for combination therapy with transarterial chemoembolization
(TACE) in unresectable HCC has been raised due to the palliative nature of TACE, and …
(TACE) in unresectable HCC has been raised due to the palliative nature of TACE, and …
Impact of anticancer drugs on the therapeutic efficacy and side effects of hepatic arterial embolization for hepatocellular carcinoma
H Ihira, T Sonomura, A Makitani, K Makitani… - JGH …, 2023 - Wiley Online Library
Abstract Background and Aim Transcatheter arterial chemoembolization (TACE) using
various anticancer drugs is often performed to treat hepatocellular carcinoma (HCC). We …
various anticancer drugs is often performed to treat hepatocellular carcinoma (HCC). We …
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness
A Sergio, C Cristofori, R Cardin, G Pivetta… - Official journal of the …, 2008 - journals.lww.com
OBJECTIVE Although transcatheter arterial chemoembolization (TACE) is effective in
hepatocellular carcinoma (HCC), it is not considered a curative procedure. Among the …
hepatocellular carcinoma (HCC), it is not considered a curative procedure. Among the …
Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy
C Hsu, PC Liang, S Morita, FC Hu, AL Cheng - Liver Cancer, 2012 - karger.com
Transarterial chemoembolization (TACE) moderately prolongs the survival of patients with
intermediate-stage hepatocellular carcinoma. Molecular targeted therapy (MTT) may …
intermediate-stage hepatocellular carcinoma. Molecular targeted therapy (MTT) may …
Chemoembolization in patients with hepatocellular carcinoma
R Lencioni - Liver cancer, 2012 - karger.com
Transcatheter arterial chemoembolization (TACE) is the standard of care for nonsurgical
patients with preserved liver function with large or multinodular noninvasive hepatocellular …
patients with preserved liver function with large or multinodular noninvasive hepatocellular …
Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international …
M Kudo, JL Raoul, HC Lee, AL Cheng, K Nakajima… - 2018 - ascopubs.org
368 Background: TACE is commonly used for patients (pts) with unresectable HCC, and
appropriate pt selection is important to obtain optimal outcomes. However, there is no …
appropriate pt selection is important to obtain optimal outcomes. However, there is no …
Related searches
- hepatocellular carcinoma transarterial chemoembolization
- survival of patients transarterial chemoembolization
- hepatocellular carcinoma survival of patients
- use of sorafenib transarterial chemoembolization
- perspectives on the design transarterial chemoembolization
- antiangiogenic therapy transarterial chemoembolization
- exploratory analysis transarterial chemoembolization
- hepatocellular carcinoma angiogenesis and invasiveness
- liver function transarterial chemoembolization
- hepatocellular carcinoma use of sorafenib
- hepatocellular carcinoma antiangiogenic therapy
- hepatocellular carcinoma anticancer drugs
- hepatocellular carcinoma liver function
- hepatocellular carcinoma exploratory analysis
- hepatocellular carcinoma chemoembolization in patients
- carcinoma treatment transarterial chemoembolization